Repository logo
 

Comparative clinical effectiveness and cost effectiveness of endovascular strategy vs open repair for ruptured abdominal aortic aneurysm: three year results of the IMPROVE randomised trial

Published version
Peer-reviewed

Change log

Authors

Sweeting, MJ 
Ulug, P 
Sweeting, MJ 
Gomes, M 
Hinchliffe, RJ 

Abstract

Objective To assess the three year clinical outcomes and cost effectiveness of a strategy of endovascular repair (if aortic morphology is suitable, open repair if not) versus open repair for patients with suspected ruptured abdominal aortic aneurysm. Design Randomised controlled trial. Participants 613 eligible patients (480 men) with a clinical diagnosis of ruptured aneurysm, of whom 502 underwent emergency repair for rupture. Interventions 316 patients were randomised to an endovascular strategy (275 with confirmed rupture) and 297 to open repair (261 with confirmed rupture). Main outcome measures Mortality, with reinterventions after aneurysm repair, quality of life, and hospital costs to three years as secondary measures. Results The maximum follow-up for mortality was 7.1 years, with two patients in each group lost to follow-up by three years. After similar mortality by 90 days, in the mid-term (three months to three years) there were fewer deaths in the endovascular than the open repair group (hazard ratio 0.57, 95% confidence interval 0.36 to 0.90), but by seven years mortality was about 60% in each group (hazard ratio 0.92, 0.75 to 1.13). Results for the 502 patients with repaired ruptures were more pronounced: three year mortality was lower in the endovascular strategy group (42% v 54%; odds ratio 0.62, 0.43 to 0.88), but after seven years there was no clear difference between the groups (hazard ratio 0.86, 0.68 to 1.08). Reintervention rates up to three years were not significantly different between the randomised groups (hazard ratio 1.02, 0.79 to 1.32); the initial rapid rate of reinterventions was followed by a much slower mid-term reintervention rate in both groups. The early higher average quality of life in the endovascular strategy versus open repair group, coupled with the lower mortality at three years, led to a gain in average quality adjusted life years (QALYs) at three years of 0.17 (95% confidence interval 0.00 to 0.33). The endovascular strategy group spent fewer days in hospital and had lower average costs of −£2605 (€2813; $3439) (95% confidence interval −£5966 to £702). The probability that the endovascular strategy is cost effective was >90% at all levels of willingness to pay for a QALY gain. Conclusions At three years, compared with open repair, an endovascular strategy for suspected ruptured abdominal aortic aneurysm was associated with a survival advantage, a gain in QALYs, similar levels of reintervention, and reduced costs, and this strategy was cost effective. These findings support the increasing use of an endovascular strategy, with wider availability of emergency endovascular repair. Trial registration Current Controlled Trials ISRCTN48334791; ClinicalTrials NCT00746122

Description

Keywords

Aged, Aneurysm, Ruptured, Aortic Aneurysm, Abdominal, Canada, Cause of Death, Cost-Benefit Analysis, Endovascular Procedures, Female, Health Care Costs, Humans, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Outcome Assessment, Health Care, Postoperative Complications, Proportional Hazards Models, Quality-Adjusted Life Years, Risk Assessment, Survival Analysis, United Kingdom, Vascular Surgical Procedures

Journal Title

BMJ

Conference Name

Journal ISSN

0959-535X
1756-1833

Volume Title

359

Publisher

BMJ
Sponsorship
Department of Health (via Imperial College London) (P14694 DS/ 2333727)
British Heart Foundation (None)
British Heart Foundation (CH/12/2/29428)
This project was funded by the UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (project No 07/37/64). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, National Health Service, or the Department of Health. Neither the funder nor the sponsor had any role in study design, data collection, analysis and interpretation of the findings.